Sector
PharmaceuticalsOpen
₹1,677.5Prev. Close
₹1,677.5Turnover(Lac.)
₹26,098.79Day's High
₹1,692.8Day's Low
₹1,674.552 Week's High
₹1,960.3552 Week's Low
₹1,498.3Book Value
₹116.6Face Value
₹1Mkt Cap (₹ Cr.)
4,03,016.29P/E
94EPS
17.85Divi. Yield
0.9510 Dec 2024
12:00 AM
EGM
12 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
31 Jan 2025
12:00 AM
Dividend
Dividend Amount: 10.5
Record Date: 06 Feb, 2025
19 Jun 2024
12:00 AM
AGM
Announcement Date: 19 Jun, 2024
Here are some of the stocks that may see significant price movement today: Sun Pharma, Vedanta, SpiceJet, etc.
The visit lasted from June 2 to June 13 and focused on checking for compliance with Good Manufacturing Practices.
Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.
The Board recommended a final dividend of ₹5.50 per share for FY25.
NLC's subsidiary has executed a PPA with Rajasthan Rajya Vidyut Utpadan Nigam Ltd. (RVUNL) for 810 MW solar power plant at Pugal Solar Park, Rajasthan
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 239.93 | 239.93 | 239.93 | 239.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 23,454.47 | 23,508.43 | 24,348.02 | 26,698.54 |
Net Worth | 23,694.4 | 23,748.36 | 24,587.95 | 26,938.47 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 15,585.98 | 14,116.05 | 12,531.93 | 7,923.84 |
yoy growth (%) | 10.41 | 12.64 | 58.15 | 3.12 |
Raw materials | -5,650.39 | -5,107.48 | -4,567.72 | -3,492.77 |
As % of sales | 36.25 | 36.18 | 36.44 | 44.07 |
Employee costs | -2,000.78 | -1,805.98 | -1,702.77 | -1,617.69 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 2,127.39 | 945.13 | 3,253 | 430.52 |
Depreciation | -1,349.95 | -1,236.43 | -561.56 | -432.23 |
Tax paid | -406.85 | -13.17 | -41.86 | 25.39 |
Working capital | -5,179.41 | -888.49 | 3,200.15 | 1,619.85 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.41 | 12.64 | 58.15 | 3.12 |
Op profit growth | 28.82 | -16.76 | 2,104.23 | 7.94 |
EBIT growth | 107.43 | -66.87 | 347.1 | 296.01 |
Net profit growth | -111.86 | -73.76 | -749.25 | 2,065.45 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 52,041.25 | 47,758.45 | 43,278.87 | 38,426.42 | 33,233.08 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 52,041.25 | 47,758.45 | 43,278.87 | 38,426.42 | 33,233.08 |
Other Operating Income | 537.19 | 738.4 | 606.81 | 228.07 | 265.06 |
Other Income | 1,965.04 | 1,354.19 | 634.52 | 921.51 | 835.52 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,677.5 | 94 | 4,02,584.41 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,859.5 | 82.46 | 1,82,147.28 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,497.6 | 25.13 | 1,20,934.05 | 1,485.4 | 1.07 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,349.4 | 59.47 | 1,13,319.98 | 474 | 0.96 | 2,385 | 224.33 |
Dr Reddys Laboratories Ltd DRREDDY | 1,270.8 | 19.84 | 1,06,137.94 | 1,200.7 | 0.63 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Dilip S Shanghvi
Non-Exec. & Independent Dir.
Gautam Doshi
Lead Independent Director
Pawan Goenka
Independent Director
Rama Bijapurkar
Company Sec. & Compli. Officer
Anoop Deshpande
Independent Director
Rolf Hoffmann
Whole Time Director
Aalok Shanghvi
Whole Time Director
Vidhi Shanghvi
Sun Pharma Advanced Res.Centre,
Tandalja,
Gujarat - 390020
Tel: 91-265-6615500
Website: http://www.sunpharma.com
Email: secretarial@sunpharma.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the larg...
Read More
Reports by Sun Pharmaceuticals Industries Ltd
What is the Sun Pharmaceutical Industries Ltd share price today?
What is the Market Cap of Sun Pharmaceutical Industries Ltd?
What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd?
What is the 52 Week High and Low of Sun Pharmaceutical Industries Ltd?
What is the CAGR of Sun Pharmaceutical Industries Ltd?
What is the shareholding pattern of Sun Pharmaceutical Industries Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
